Understanding the complex interaction among pro‐angiogenic factors (ANG/Tie‐2/VEGF‐C) and their relationship with ER or HER‐2 status underscores the clinical relevance of these biomarkers in detecting ALNM in breast cancer patients. This evidence concerns the gene VEGFC and breast carcinoma.